EIB finances Almirall’s research into new skin disease treatments
The European Investment Bank (EIB) has granted a €120 multimillion loan to Spanish pharmaceutical company Almirall under the investment plan for Europe.
The European Investment Bank (EIB) has granted a €120 multimillion loan to Spanish pharmaceutical company Almirall under the investment plan for Europe.
In September, Spanish pharmaceutical company Almirall acquired Allergan’s US medical dermatology unit portfolio by using a €400 million bridge loan. It acquired brands Aczone (dapsone), Tazorac (tazarotene), Azelex (azelaic acid) and Cordran Tape (fludroxycortide).